biostudies-literatureUnknown43Werner B<h4>Objective</h4>To investigate cell-free DNA (cfDNA) in plasma and ascites and its association with clinical outcomes (paracentesis-free interval, overall survival) and CA125 level in participants with advanced ovarian cancer, treated with palliative intraperitoneal bevacizumab to delay re-accumulation of ascites.<h4>Methods</h4>cfDNA was extracted from 0.3 to 1 mL samples from 20/24 participants of the REZOLVE trial. Standard and methylation-specific PCRs were performed to measure 3 biomarkers: total cfDNA (Alu), tumour-derived cfDNA (ctDNA, methylated IFFO1 promoter) and endothelium-derived cfDNA (ec-cfDNA, unmethylated CDH5 promoter). Values were correlated to clinical outcomes.<h4>Results</h4>cfDNA was detected in all samples, with higher yield in ascites (mean 669 ng/mL) than plasmaTranslational oncology101914https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966381biostudies-literatureCell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.PMC10966381Cummins MMShannon CFriedlander MYip SFord CEEspinoza DAnanda SWarton KWerner BMileshkin LSjoquist KMChang GfalseCell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.<h4>Objective</h4>To investigate cell-free DNA (cfDNA) in plasma and ascites and its association with clinical outcomes (paracentesis-free interval, overall survival) and CA125 level in participants with advanced ovarian cancer, treated with palliative intraperitoneal bevacizumab to delay re-accumulation of ascites.<h4>Methods</h4>cfDNA was extracted from 0.3 to 1 mL samples from 20/24 participants of the REZOLVE trial. Standard and methylation-specific PCRs were performed to measure 3 biomarkers: total cfDNA (Alu), tumour-derived cfDNA (ctDNA, methylated IFFO1 promoter) and endothelium-derived cfDNA (ec-cfDNA, unmethylated CDH5 promoter). Values were correlated to clinical outcomes.<h4>Results</h4>cfDNA was detected in all samples, with higher yield in ascites (mean 669 ng/mL) than plasma2024-01-01T00:00:00Z2024 May2026-07-09T10:39:24.033Z2026-07-09T10:26:11.201ZS-EPMC109663813841729210.1016/j.tranon.2024.101914